US › Healthcare

Lexeo Therapeutics, Inc. Common Stock (LXEO)

US · Healthcare · Biotechnology

$4.41+5.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-20.2M
Profit YoY
+38.2%
EPS
$-0.25
EPS estimate
$-0.30

EPS came in at -0.25 against a street estimate of -0.30 — a beat of 16.7%.

Key statistics

Market cap
$329.8M
Forward P/E
0.0
P/B
1.40
Book value
$3.12
EPS (TTM)
$-1.12
52-week high
$10.99
52-week low
$3.99
50-day MA
$4.70
200-day MA
$6.93
Beta
1.47

Analyst view

Analysts rate Lexeo Therapeutics, Inc. Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $20.89.

Shareholding

Insiders
0.60%
Institutions
114.54%

Largest institutional holders

FundStake
Paradigm Biocapital Advisors LP7.88%
BlackRock Inc6.51%
Affinity Asset Advisors, LLC6.43%
RA Capital Management, LLC6.37%
HHG PLC6.34%
Vestal Point Capital LP5.70%
Frazier Life Sciences Management, L.P.5.63%
Vanguard Group Inc4.96%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lexeo Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.